Bruchanski final x

361
-1

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
361
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
20
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Bruchanski final x

  1. 1. <ul><li>Lawrence R. Wechsler, MD. N Engl J Med 364;22 </li></ul>Bruchanski Natalia Alameda County Medical Center Highland General Hospital August 2011 Intravenous Thrombolytic Therapy for Acute Ischemic Stroke
  2. 3. Statistics <ul><li>795,000 new strokes each year, in US </li></ul><ul><li>More than 150 000 deaths each year, 436 each day. </li></ul><ul><li>1 stroke every 53 seconds, 1 death from stroke every 3.3 minutes! </li></ul><ul><li>More than 25% of stroke survivors older than age 65 years are disabled 6 months later </li></ul>
  3. 4. Acute Medical Treatment of Stroke <ul><li>Restore Blood Flow </li></ul><ul><ul><li>Thrombolytics </li></ul></ul><ul><ul><li>Mechanical devices </li></ul></ul><ul><li> Stroke progression or recurrent thromboembolism </li></ul><ul><ul><li>Anticoagulants </li></ul></ul><ul><ul><li>Antiplatelet agents </li></ul></ul>
  4. 5. Recombinant Tissue Plasminogen Activator (rtPA)
  5. 6. Tissue Plasminogen Activator for Acute Ischemic Stroke The National Institute of Neurological Disorders and Stoke rt-PA Stroke Study Group N Engl J Med 333; 24. Dec 1995 <ul><li>Approved by The US Food and Drug Administration (FDA) in 1996 </li></ul><ul><li>National Institute of Neurological Disorders and Stroke (NINDS) rtPA Stroke Study : </li></ul><ul><li>• RCT. 624 patients </li></ul><ul><li>• G iven 0.9 mg/kg IV, maximum 90 mg within 3 hours of symptoms </li></ul><ul><li>onset </li></ul><ul><li>Results : </li></ul><ul><li>• Favorable outcomes * achieved as compared with placebo at 90 </li></ul><ul><li>days, 6 months and 1 year. </li></ul><ul><li>Relative increase in recovery of 32% in tPA vs. 20% in placebo. P<0.05 </li></ul><ul><li>• Symptomatic brain hemorrhage within 36 hs after onset of stroke, </li></ul><ul><li>occurred in 6.4% in rtPA vs. 0.6% in placebo (p<0.001) Patients with symptomatic intracranial hemorrhage had more severe deficits at base line (median NIHSS score, 20) than the study population (median NIHSS score, 14) </li></ul><ul><li>• Mortality rate in the 2 treatment groups similar at 3 months </li></ul><ul><li>17% in tPA group vs. 21% in placebo p=0.30 </li></ul><ul><li>* Outcomes measured: Barthel Index, Mod Rankin Scale, GSW, NIHSS </li></ul>
  6. 7. tPA tPA Placebo Placebo 32 20 17 6.4 21 0.1 Excellent Recovery (%) Total Death Rate (%) Hemorrhage NINDS rt-PA Stroke Trial N Engl J Med 333; 24. Dec 1995
  7. 8. IV tPA for Acute Ischemic Stroke, Negative studies ECASS I ECASS II ATLANTIS Study/ Year RCT/1995 RCT/1998 RCT/1999 N 620 800 613 rtPA dose 1.1 mg/Kg 0.9 mg/Kg 0.9 mg/Kg Treatment Window 0-6 hs 0-6 hs 3-5 hs Primary Outcome BI, RS at 90 days BI, RS at 90 days NIHHS, BI, RS and GSW at 30 and 90 days Results No difference in Primary end point with increase mortality and risk of ICH in rtPA group Similar to ECASS I without increase in mortality in control group No differences in primary end point between groups. Increase in ICH rate and mortality Inconvenients Less strict BP control, higher dose, and window 80% were treated at 4-5 h Average time to Tx 4.5 hs Observations Subgroup treated within 3 hs had benefit with rtPA
  8. 9. RCT of IV tPA for Acute Ischemic Stroke Study N Dose Time window ECASS I 650 1.1 0-6 NINDS 624 0.9 0-3 ECASS II 800 0.9 0-6 ATLANTIS A 142 0.9 0-6 ATLANTIS B 619 0.9 3-5
  9. 10. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet.  2004; 363(9411):768-74 Time (mins) Odds Ratio for favorable outcomes 95% CI Interval 0-90 2.8 1.8-4.5 91-180 1.5 1.1-2.1 181-270 1.4 1.1-1.9 271-360 1.2 0.9-1.5
  10. 11. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet.  2004; 363(9411):768-74
  11. 12. ECASS III <ul><li>RCT. 821 patients. 2008 </li></ul><ul><li>Intravenous rtPA 0.9 mg/kg IV vs. Placebo </li></ul><ul><li>3-4.5 hours after onset of symptoms (Average time 3h, 59 min) </li></ul><ul><li>Additional Exclusion Criteria: More than 80 years old </li></ul><ul><li>Severe Stroke (NIHSS >25 or hypodensity > 1/3 of MCA on CT) </li></ul><ul><li>Prior treatment with anticoagulants </li></ul><ul><li>History of both stroke and Diabetes </li></ul><ul><li>Results: </li></ul><ul><li>- Favorable outcome : 52.4 % in rtPA vs.45.2% in placebo Odds </li></ul><ul><li>ratio 1.34, 95% CI, 1.02-1.76; p=0.04 </li></ul><ul><li>- Symptomatic ICH rate: 2.4 % in rtPA vs. 0.2 % in placebo group. P=0.008 </li></ul><ul><li>- Mortality: 7.7 % in rtPA vs. 8.4 % in placebo </li></ul>
  12. 13. American Heart Association Recommendations Stroke , 2007, 2009 <ul><li>• 2007 </li></ul><ul><li>Intravenous rtPA (0.9 mg/kg, maximum dose 90 mg) is recommended for selected patients who may be treated within 3 hours of onset of ischemic stroke (Class I, Level of Evidence A) </li></ul><ul><li>• 2009,Addendum: </li></ul><ul><li>Intravenous rtPA should be given to eligible patients who can be treated in the time period of 3 to 4.5 hours after stroke (Class I, level of evidence B). This window frame adds 4 new exclusion citeria. </li></ul>
  13. 14. Inclusion Criteria <ul><li>Diagnosis of Ischemic Stroke causing measurable neurologic deficit </li></ul><ul><li>Onset of symptoms < 3 hours before start of treatment or in selected cases < 4.5 hours </li></ul><ul><li>Age > 18 </li></ul>
  14. 15. Exclusion Criteria
  15. 16. Exclusion Criteria
  16. 17. Discussion Question <ul><li>How would you evaluate, and explain to a patient, the risk/benefit balance of using rt-PA? </li></ul><ul><li>To what extent do you think the claims of this review can be applied to our work at Highland? </li></ul>
  17. 18. <ul><li>Number Needed to Treat or Harm: </li></ul><ul><li>_________1_________ </li></ul><ul><li>Absolute Increase in Benefit or Risk </li></ul>Conclusions
  18. 19. <ul><li>Likelihood of Being Harmed or Helped: </li></ul><ul><li>____Absolute Benefit Increase__ </li></ul><ul><li>Absolute Risk Increase </li></ul><ul><li>= </li></ul><ul><li>____12% better outcome____ </li></ul><ul><li>6% symptomatic ICH </li></ul>Conclusions
  19. 20. <ul><li>For patients who would have been included in the NINDS study, therapy with rt-PA is twice as likely to help their neurological deficit as it is to cause a symptomatic ICH. </li></ul>Conclusions
  20. 21. Conclusion <ul><li>The available evidence suggests rt-PA has a significant potential to improve neurologic outcomes in people who meet the inclusion criteria of the NINDS trial and no accepted exclusion criteria. </li></ul><ul><li>Significant practical barriers exist to acting on this data in many settings. </li></ul>
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×